ZARIA SMITH — Lobbyist Profile | Poliscope

ZARIA SMITH

Filings

13

Clients

1

Firms

1

Years active

2023–2026

Associated filing income

—

How to read the money

Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.

Clients represented

Client	Filings	Years
NOVOCURE INC.	13	2023–2026

Lobbying firms

Firm	Filings	Years
NOVOCURE INC.	13	2023–2026

Bills explicitly cited in this lobbyist’s assigned issues (18)

No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.

Ensuring Patient Access to Critical Breakthrough Products Act

Client: NOVOCURE INC. · Firm: NOVOCURE INC.

Open original LDA filing ↗

Cited source text

General Medicare Issues. H.R.5343/S.1717 - Ensuring Patient Access to Critical Breakthrough Products Act of 2025.

Ensuring Patient Access to Critical Breakthrough Products Act of 2025

Client: NOVOCURE INC. · Firm: NOVOCURE INC.

Open original LDA filing ↗

Cited source text

General Medicare Issues. H.R.5343/S.1717 - Ensuring Patient Access to Critical Breakthrough Products Act of 2025.

Original LDA source filings (13)

Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.

NOVOCURE INC. via NOVOCURE INC.

2026 · first_quarter · Q1

Firm income: —Client expense: $180,000Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

General Medicare Issues. H.R.5343/S.1717 - Ensuring Patient Access to Critical Breakthrough Products Act of 2025.

TAR

Tariff (miscellaneous tariff bills)

Tariff issues, specifically related to medical device 232.

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Source: Senate LDA

Show 14 more cited filings

Ensuring Patient Access to Critical Breakthrough Products Act of 2025

Client: NOVOCURE INC. · Firm: NOVOCURE INC.

Open original LDA filing ↗

Cited source text

General Medicare Issues. S.1717 - Ensuring Patient Access to Critical Breakthrough Products Act of 2025.

Ensuring Patient Access to Critical Breakthrough Products Act of 2025

Client: NOVOCURE INC. · Firm: NOVOCURE INC.

Open original LDA filing ↗

Cited source text

General Medicare Issues. H.R.5343/S.1717 - Ensuring Patient Access to Critical Breakthrough Products Act of 2025.

Ensuring Patient Access to Critical Breakthrough Products Act of 2025

Client: NOVOCURE INC. · Firm: NOVOCURE INC.

Open original LDA filing ↗

Cited source text

General Medicare Issues. H.R.5343/S.1717 - Ensuring Patient Access to Critical Breakthrough Products Act of 2025.

Ensuring Patient Access to Critical Breakthrough Products Act of 2024

Client: NOVOCURE INC. · Firm: NOVOCURE INC.

Open original LDA filing ↗

Cited source text

General Medicare Issues. H.R.1691/S.5349 - Ensuring Patient Access to Critical Breakthrough Products Act of 2024.

Ensuring Patient Access to Critical Breakthrough Products Act of 2024

Client: NOVOCURE INC. · Firm: NOVOCURE INC.

Open original LDA filing ↗

Cited source text

General Medicare Issues. H.R.1691/S.5349 - Ensuring Patient Access to Critical Breakthrough Products Act of 2024.

Ensuring Patient Access to Critical Breakthrough Products Act of 2024

Client: NOVOCURE INC. · Firm: NOVOCURE INC.

Open original LDA filing ↗

Cited source text

General Medicare Issues. H.R.1691/S.5349 - Ensuring Patient Access to Critical Breakthrough Products Act of 2024.

Ensuring Patient Access to Critical Breakthrough Products Act of 2024

Client: NOVOCURE INC. · Firm: NOVOCURE INC.

Open original LDA filing ↗

Cited source text

General Medicare Issues. H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023.

Ensuring Patient Access to Critical Breakthrough Products Act of 2024

Client: NOVOCURE INC. · Firm: NOVOCURE INC.

Open original LDA filing ↗

Cited source text

General Medicare Issues. H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023.

Ensuring Patient Access to Critical Breakthrough Products Act of 2024

Client: NOVOCURE INC. · Firm: NOVOCURE INC.

Open original LDA filing ↗

Cited source text

General Medicare Issues. H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023.

Ensuring Patient Access to Critical Breakthrough Products Act of 2024

Client: NOVOCURE INC. · Firm: NOVOCURE INC.

Open original LDA filing ↗

Cited source text

General Medicare Issues. H.R.1691/S.5349 - Ensuring Patient Access to Critical Breakthrough Products Act of 2024.

Ensuring Patient Access to Critical Breakthrough Products Act of 2024

Client: NOVOCURE INC. · Firm: NOVOCURE INC.

Open original LDA filing ↗

Cited source text

General Medicare Issues. H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023.

Ensuring Patient Access to Critical Breakthrough Products Act of 2024

Client: NOVOCURE INC. · Firm: NOVOCURE INC.

Open original LDA filing ↗

Cited source text

General Medicare Issues. H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023.

Ensuring Patient Access to Critical Breakthrough Products Act of 2024

Client: NOVOCURE INC. · Firm: NOVOCURE INC.

Open original LDA filing ↗

Cited source text

General Medicare Issues. H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023.

Ensuring Patient Access to Critical Breakthrough Products Act of 2024

Client: NOVOCURE INC. · Firm: NOVOCURE INC.

Open original LDA filing ↗

Cited source text

General Medicare Issues. H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023.

Show 9 more original filings

NOVOCURE INC. via NOVOCURE INC.

2025 · first_quarter · Q1

Firm income: —Client expense: $110,000Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

General Medicare Issues. H.R.1691/S.5349 - Ensuring Patient Access to Critical Breakthrough Products Act of 2024.

VET

Veterans

Veterans Affairs / Veterans Health Administration (VHA) issues.

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

NOVOCURE INC. via NOVOCURE INC.

2024 · fourth_quarter · Q4

Firm income: —Client expense: $110,000Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

General Medicare Issues. H.R.1691/S.5349 - Ensuring Patient Access to Critical Breakthrough Products Act of 2024.

VET

Veterans

Veterans Affairs / Veterans Health Administration (VHA) issues.

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

NOVOCURE INC. via NOVOCURE INC.

2024 · third_quarter · Q3

Firm income: —Client expense: $120,000Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

VET

Veterans

Veterans Affairs / Veterans Health Administration (VHA) issues.

MMM

Medicare/Medicaid

General Medicare Issues. H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023.

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

NOVOCURE INC. via NOVOCURE INC.

2024 · second_quarter · Q2

Firm income: —Client expense: $220,000Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

VET

Veterans

Veterans Affairs / Veterans Health Administration (VHA) issues.

MMM

Medicare/Medicaid

General Medicare Issues. H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023.

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

NOVOCURE INC. via NOVOCURE INC.

2024 · first_quarter · Q1

Firm income: —Client expense: $200,000Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

General Medicare Issues. H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023.

VET

Veterans

Veterans Affairs / Veterans Health Administration (VHA) issues.

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

NOVOCURE INC. via NOVOCURE INC.

2023 · fourth_quarter · Q4

Firm income: —Client expense: $120,000Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

General Medicare Issues. H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023.

VET

Veterans

Veterans Affairs / Veterans Health Administration (VHA) issues.

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

NOVOCURE INC. via NOVOCURE INC.

2023 · third_quarter · Q3

Firm income: —Client expense: $140,000Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

General Medicare Issues. H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023.

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

NOVOCURE INC. via NOVOCURE INC.

2023 · second_quarter · 2A

Firm income: —Client expense: $180,000Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

TRA

Transportation

TSA Issues.

VET

Veterans

Veteran Affairs Issues.

MMM

Medicare/Medicaid

General Medicare Issues. H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023.

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, Transportation Security Administration (TSA), White House Office

NOVOCURE INC. via NOVOCURE INC.

2023 · second_quarter · Q2

Firm income: —Client expense: $110,000Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

TRA

Transportation

TSA Issues.

MMM

Medicare/Medicaid

General Medicare Issues. H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023.

VET

Veterans

Veteran Affairs Issues.

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, Transportation Security Administration (TSA), White House Office